gabapentin has been researched along with glyburide in 16 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 11 (68.75) | 29.6817 |
2010's | 5 (31.25) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bhargava, VK; Dixit, RK | 1 |
Aranda, H; Dooley, DJ; Eckhardt, K; Feuerstein, TJ; Freiman, TM; Heinemeyer, J; Kukolja, J; Rominger, A; Zentner, J | 1 |
Hogan, Q; Kwok, WM; McCallum, B; Sapunar, D; Sarantopoulos, C | 1 |
Flores-Murrieta, FJ; Granados-Soto, V; Mixcoatl-Zecuatl, T | 1 |
Granados-Soto, V; Medina-Tato, DA; Ortiz, MI; Palma-Martínez, J; Sarmiento-Heredia, D | 1 |
Fernández-Martínez, E; Izquierdo-Vega, JA; Macías, A; Ortiz, MI; Ponce-Monter, HA; Rangel-Flores, E; Sánchez-Gutiérrez, M | 1 |
1 review(s) available for gabapentin and glyburide
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for gabapentin and glyburide
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Effect of glibenclamide in gabapentin antinociception.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Glyburide; Hypoglycemic Agents; Male; Morphine; Pain Measurement; Potassium Channels; Rats; Rats, Wistar | 2001 |
Modulation of K+-evoked [3H]-noradrenaline release from rat and human brain slices by gabapentin: involvement of KATP channels.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Gabapentin; gamma-Aminobutyric Acid; Glyburide; Hippocampus; Humans; Hypoglycemic Agents; In Vitro Techniques; Male; Neocortex; Norepinephrine; Pinacidil; Potassium Channels; Potassium Chloride; Rats; Rats, Wistar; Retrospective Studies; Vasodilator Agents | 2001 |
ATP-sensitive potassium channels in rat primary afferent neurons: the effect of neuropathic injury and gabapentin.
Topics: Acetates; Amines; Animals; ATP-Binding Cassette Transporters; Basal Ganglia; Cyclohexanecarboxylic Acids; Diazoxide; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Ganglia, Spinal; Glyburide; KATP Channels; Male; Neurons, Afferent; Neuroprotective Agents; Pain; Peripheral Nervous System Diseases; Pinacidil; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Inwardly Rectifying; Rats; Rats, Sprague-Dawley | 2003 |
The nitric oxide-cyclic GMP-protein kinase G-K+ channel pathway participates in the antiallodynic effect of spinal gabapentin.
Topics: Amines; Analgesics; Animals; Apamin; Carbazoles; Charybdotoxin; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclohexanecarboxylic Acids; Diazoxide; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gabapentin; gamma-Aminobutyric Acid; Glyburide; Indazoles; Indoles; Injections, Spinal; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Okadaic Acid; Oxadiazoles; Pain; Pinacidil; Potassium Channel Blockers; Potassium Channels; Protein Kinase Inhibitors; Quinoxalines; Rats; Rats, Wistar; Signal Transduction; Spinal Nerves; Stereoisomerism; Time Factors; Vasodilator Agents | 2006 |
Possible activation of the NO-cyclic GMP-protein kinase G-K+ channels pathway by gabapentin on the formalin test.
Topics: 4-Aminopyridine; Amines; Analgesics; Animals; Apamin; Carbazoles; Charybdotoxin; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Glyburide; Indoles; Naloxone; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pain Measurement; Potassium Channel Blockers; Potassium Channels; Rats; Rats, Wistar; Tolbutamide | 2006 |
Pharmacological interaction between gabapentin and glibenclamide in the formalin test in the diabetic rat.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Drug Interactions; Gabapentin; gamma-Aminobutyric Acid; Glyburide; KATP Channels; Male; Pain Measurement; Rats; Rats, Wistar | 2010 |